Modofi Bio, a New Haven, CT-based company which specializes in DNA modification as a novel approach to target cancer, raised additional $4.3M in Seed funding.
The round included existing investors Connecticut Innovation, HighCape Capital, Advantage Capital (Ironwood) and the National Brain Tumor Society, while also adding new investors Pathway BioVentures, The Sontag Foundation, and BrightEdge, the impact investment and innovation arm of the American Cancer Society.
The company intends to use the funds to further advance its lead molecules towards IND-enabling studies and phase I clinical trials.
Modifi Bio is a company which specializes in direct DNA modification developing novel therapeutics by targeting tumor-associated DNA repair defects. The company has offices and laboratories at the Elm City Bioscience Center, a newly renovated 110,000 square-foot facility within walking distance of Yale that supports emerging New Haven biotechnology companies.
FinSMEs
17/10/2023